Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-009 (Nab-sirolimus) in Leigh Syndrome
NCT03747328Phase 2Withdrawn
- Sponsor
- Aadi Bioscience, Inc.
- Start
- Apr 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of nab-sirolimus in Leigh syndrome, sponsored by Aadi Bioscience, Inc. Primary endpoint: Incidence of treatment emergent adverse events at 24 weeks. Planned start Apr 2022; status: withdrawn.
02
Drugs
nab-sirolimus
03
Conditions
Leigh syndrome
Beyond the preview
Go deeper on NCT03747328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03747328.